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Background: Plasmodium vivax merozoite surface protein-1 (MSP-1) is an antigen considered to be one of the
leading malaria vaccine candidates. PvMSP-1 is highly immunogenic and evidences suggest that it is target for
protective immunity against asexual blood stages of malaria parasites. Thus, this study aims to evaluate the
acquired cellular and antibody immune responses against PvMSP-1 in individuals naturally exposed to malaria
infections in a malaria-endemic area in the north-eastern Amazon region of Brazil.
Methods: The study was carried out in Paragominas, Pará State, in the Brazilian Amazon. Blood samples were
collected from 35 individuals with uncomplicated malaria. Peripheral blood mononuclear cells were isolated and
the cellular proliferation and activation was analysed in presence of 19 kDa fragment of MSP-1 (PvMSP-119) and
Plasmodium falciparum PSS1 crude antigen. Antibodies IgE, IgM, IgG and IgG subclass and the levels of TNF, IFN-γ
and IL-10 were measured by enzyme-linked immunosorbent assay.
Results: The prevalence of activated CD4+ was greater than CD8+ T cells, in both ex-vivo and in 96 h culture in
presence of PvMSP-119 and PSS1 antigen. A low proliferative response against PvMSP-119 and PSS1 crude antigen
after 96 h culture was observed. High plasmatic levels of IFN-γ and IL-10 as well as lower TNF levels were also
detected in malaria patients. However, in the 96 h supernatant culture, the dynamics of cytokine responses differed
from those depicted on plasma assays; in presence of PvMSP-119 stimulus, higher levels of TNF were noted in
supernatant 96 h culture of malaria patient’s cells while low levels of IFN-γ and IL-10 were verified. High frequency
of malaria patients presenting antibodies against PvMSP-119 was evidenced, regardless class or IgG subclass.
PvMSP-119-induced antibodies were predominantly on non-cytophilic subclasses.
Conclusions: The results presented here shows that PvMSP-119 was able to induce a high cellular activation,
leading to production of TNF and emphasizes the high immunogenicity of PvMSP-119 in naturally exposed
individuals and, therefore, its potential as a malaria vaccine candidate.
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Malaria remains a serious public health problem causing
high levels of morbidity and mortality in malaria-
endemic regions. There were an estimated 219 million
cases of malaria and 660,000 deaths in 2010 [1]. Among
the five Plasmodium species responsible for natural in-
fection of human, Plasmodium vivax has the widest geo-
graphical distribution, being the second leading cause of
malaria [1]. Although usually considered a benign infec-
tion, severe P. vivax malaria cases have been reported
worldwide [2-10]. In Brazil, P. vivax accounts for around
85% of clinical cases [11].
Since an effective malaria vaccine has long been envis-
aged as a potential tool for malaria control, two import-
ant points for its development are the identification of
antigens that elicit the relevant immunological machin-
ery and the correlation between the resulting immune
system products and the clinical and/or parasitological
protection induced. In this context, several antigens are
being evaluated in clinical trials. To date, one candidate
vaccine is currently being assessed in Phase 3 clinical tri-
als and approximately 20 others in Phase 1 or Phase 2
trials [1]. Among these antigens, P. vivax merozoite sur-
face protein-1 (PvMSP-1) is a promising candidate.
MSP-1 is the most abundant and best-studied blood-
stage antigen [12]. MSP-1 is a 190–230 kDa protein
present in almost all Plasmodium species, being synthe-
sized in a precursor form during schizogony. Post-
translational proteolytic processing of the MSP-1 precur-
sor molecule generates different fragments (83, 28–30,
38–45 and 42 kDa). The 42 kDa fragment is processed
to a 33 kDa and a 19 kDa fragments, leaving a
membrane-anchored 19 kDa fragment (MSP-119) on the
parasite surface after its internalization in the erythro-
cyte [13-15].
The potential of PvMSP-1 as a vaccine candidate is
based on previous studies that reported that it is highly
immunogenic under natural conditions of exposure
[16-24] and that it could partially protect Saimiri mon-
keys [25]. Several studies have provided evidences that
MSP-119 is a target for protective immunity against
asexual blood stages of malaria parasites [26-28]. This
protective immunity has been shown to correlate with
levels of anti- MSP-119 antibodies and it is also
dependent of CD4 T cells [27,29,30].
Given the cumulative data supporting the potential of
PvMSP-1 as a malaria vaccine, and the substantial data
generated through studies in human indicating that both
humoral and cellular immune responses are needed to pro-
tect against malaria, the present study aims to evaluate the
acquired cellular and antibody immune responses against
PvMSP-119 in individuals naturally exposed to P. vivax or
Plasmodium falciparum infections in a malaria-endemic
area in the north-eastern Amazon region of Brazil.Methods
Study setting, participants, and blood collection
The study was carried out in Paragominas (47°36′ 09.63“W,
03°12′ 11.02” S), Pará State, in the Brazilian Amazon.
The samples were collected in 2004. The individuals
were studied by means of a questionnaire, whereby all
relevant information, including personal and epidemio-
logical data, were collected.
Written informed consent was obtained from all vol-
unteer donors and 10 ml of venous blood samples were
drawn in Vacutainer® EDTA tubes (Becton Dickinson,
Oxnard, CA) from 35 individuals with uncomplicated
malaria at the Hospital Municipal de Paragominas
(HMP). Blood samples from 17 individuals living in
Paragominas but with no history of current or previous
malaria episodes were included in the study as non-
infected control individuals. Blood collection was
performed at the day of diagnosis and patients were
treated, according to the Brazilian Ministry of Health
standards for malaria therapy, immediately after blood
sample collection.
Thin and thick blood smears were examined for iden-
tification of malaria parasite and determination of para-
sitaemia by two expert malaria microscopists from HMP
and from the Laboratory of Malaria Research (Fiocruz,
Rio de Janeiro, Brazil) which is a reference centre in
malaria diagnosis for the Brazilian Ministry of Health.
Blood smears from all subjects were stained with Giemsa
and examined under 1,000-fold magnification. Parasit-
aemia was determined by counting parasites in reference
to 200 white blood cells in thick blood films, and the
number of the blood parasites per millilitre was
calculated.
Nonendemic control blood samples from five individ-
uals of the laboratory staff (Rio de Janeiro, Brazil) who
had neither history of malaria nor contact with a malaria
transmission area, were included in the study as ‘Rio
controls’. The study was reviewed and approved by the
Fundação Oswaldo Cruz and Instituto Evandro Chagas
Ethical Committees.
Isolation of peripheral blood mononuclear cells (PBMC)
The blood samples were centrifuged for 10 min, 400 × g
and, after removal of plasma, the corresponding volume
of RPMI-1640 (Sigma, St. Louis, Mo) medium con-
taining 15 mM glutamin (Sigma), 10 mM Hepes (Sigma),
200 U/ml penicillin (Gibco), 200 μg/ml streptomycin
(Gibco), 3 mg/ml gentamicyn (Sigma) and 2 g/L sodium
bicarbonate (Sigma) was added. Subsequently, PBMC
were isolated by density gradient centrifugation (Fycoll-
Hypaque) and were washed twice in serum-free RPMI
1640 medium (Sigma). The cells were cryopreserved
according to the method described by Ichino and
Ishikawa [31]. Briefly, cells were resuspended in 4°C
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with an equal volume of cold RPMI-1640 containing
20% dimethyl sulfoxide (Sigma) and transferred to
cryotubes that were immersed in a cold ethanol bath
(4°C) and placed in a −70°C freezer for at least 12 h. The
samples were then transferred to a liquid nitrogen
storage tank. After freezing for up to 30 days, the cells
were thawed and the viability was assessed using trypan
blue staining. The thawing of PBMC was performed by
the immersion of cryotubes in a 37°C water-bath,
followed by two washes in RPMI-1640 medium (4°C) for
10 min, 400 × g.
Recovery and viability after cryopreservation
The number of viable cells was verified immediately
after thawing of PBMC (ex-vivo) by cytometry flow using
7-aminoactinomycin D (7-AAD). This rapid and sensi-
tive method allows the discrimination of live cells from
apoptotic or necrotic cells [32]. The cells were then in-
cubated for 20 min at 4°C with 300 μl of 10 μg/ml of
7-AAD (Sigma) in phosphate-buffered saline (PBS)
containing 2% foetal calf serum (Hyclone) and 0.1% so-
dium azide. After incubation, 300 μl of 2% paraformalde-
hyde were added to the samples. Labelled samples were
analysed in a FACSCalibur (Becton Dickinson and Com-
pany, Franklin Lakes, USA) and red fluorescence from
7-AAD was filtered through a 675 nm long pass filter.
Approximately 10,000 events were analysed for each
sample.
Plasmodium falciparum crude extracts preparation
The PSS1 P. falciparum strain (Peixoto de Azevedo,
Brazil) was cultivated in vitro according to the method
described by Trager and Jensen [33]. The P. falciparum
crude extract was obtained from infected erythrocytes
with parasitaemia above 6%. Parasitized erythrocytes
with a predominance of schizonts were washed three
times with PBS. The lysis of infected erythrocytes was
done by addition of 0.1% saponin and gentle shaking for
15 min. The lysates were ultrasonicated in the presence
of 1 mM phenylmethylsulfonyl fluoride and centrifuged
7,000 × g for 15 min at 4°C in order to eliminate the cel-
lular debris.
Cellular proliferation assay
Cellular proliferation was analysed by using the vital
staining carboxyfluorescein diacetate succinimidyl ester
(CFSE, Molecular Probes). The PBMC were ressuspended
in 1 ml of PBS plus 0,01% bovine serum albumin
(BSA, Sigma) at 37°C. Two microlitres of a stock solution
of CFSE (5 μM) were added in 1 ml of cellularsuspension containing up to 1x106 cells/ml. The sam-
ples were then incubated for 10 min at 37°C. Five
millilitres of RPMI-1640 at 4°C were added and the
samples were incubated for 5 min in ice-bath. After in-
cubation, the cells were washed three times with RPMI-
1640 and then ressuspended with 1 ml RPMI-1640
(Sigma) medium containing 15 mM glutamin (Sigma),
10 mM Hepes (Sigma), 200 U/ml penicillin (Gibco),
200 μg/ml streptomycin (Gibco), 3 mg/ml gentamicin
(Sigma), 3,7 g/l sodium bicarbonate (Isofar), 100 mM
piruvate (Sigma),14 mM β-mercaptoetanol (Sigma) and
10% of inactivated foetal calf serum (FCS) (complete
medium). The PBMC were distributed 2.5 × 105 cells/
well in triplicate in 96-well flat-bottom microtiter plates
(Falcon) in final volume of 200 μl of complete medium
alone or in the presence of 5 μg/ml phytohaemagglu-
tinin (PHA), 10 μg/ml P. falciparum crude extract or
PvMSP-119 (kindly provided by Dr. Mauricio Rodrigues
and Dra. Irene Soares) and, then, incubated at 37°C in 5%
CO2 for 48 or 96 h. After culture, the cellular proliferation
was analysed using a FACSCalibur flow cytometer.
Determination of cellular activation
The determination of cellular activation was done by using
monoclonal antibodies against CD25, CD4, CD8 and
CD21. The protocol consisted of the addition of 5-10 μl of
the optimal antibody dilution to 5 × 105 cells in 50 μl PBS
containing 2% foetal calf serum and 0.1% sodium azide
(azide PBS), followed by incubation for 20–30 min at 4°C.
After two washes with PBS, the cells were resuspended in
200 μl of azide PBS. The cells were then fixed with a 2%
paraformaldehyde solution and maintained in the dark
until the analysis in a FACSCalibur flow cytometer. At
least 10,000 events were analysed.
Enzyme-linked immunosorbent assay (ELISA) for PvMSP-119
Microtiter 96-well plates (Nunc Maxisorp) were coated
overnight at room temperature with 50μl of 4μg/ml
PvMSP-119 protein in 0,05 M carbonate-bicarbonate
buffer, pH 9.6. Plates were washed three times with PBS
containing 0,05% Tween 20 (PBS/T20). Uncoated sites
were blocked for 2 h at room temperature with 200μl of
PBS/T20 containing 5% powdered-milk. After incuba-
tion, 50μl of the plasma sample diluted 1:50 in
powdered-milk-containing PBS/T20 were added and the
plates were incubated for 2 h at room temperature.
Plates were washed thrice with PBS/T20 and 50μl/well
of mouse anti-human IgE, IgM, IgG or IgG subclass
(Sigma) peroxidase conjugated, in optimal antibody dilu-
tion in PBS, was added. Plates were incubated for 1 h at
37°C. After washing the plates with PBS/T20, 50 μL of a
solution containing 1 mg/ml of OPD (Sigma) and 15 μl
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added. After incubation for 10–15 min at room
temperature in the dark, the reaction was stopped with
50 μl/well of H2SO4. The absorbance was read at
405 nm in a spectrophotometer (Spectra Max 250; Mo-
lecular Devices, Sunnyvale, CA).
The cut-off value was determined as the mean optical
density (OD) plus two standard deviations from controls
that never visited malaria endemic areas. To standardize
the OD data obtained in different experiments, OD
index was calculated for each immunoglobulin deter-
mination as the ratio of the observed OD to the cut-off
values. A sample with an OD index > 1.0 was considered
positive.Assays for cytokine detection
The cytokine levels in plasma and supernatant cultures
samples were measured by ELISA using reagents from
BD Biosciences Pharmingen, USA. Briefly, 100 μl of the
capture monoclonal anti-human TNF, IFN-γ or IL-10
antibodies in optimal dilutions were used to coat 96-well
plates for 14 h at 4°C. After washing and blocking, 100μl
of plasma samples diluted 1:2 or supernatant of the cul-
tures were added to duplicated wells and incubated for
24 h at 4°C. After the samples were washed, biotinylated
anti-human cytokine were added and the plates were in-
cubated for 1 h at room temperature. The presence of
bound antibodies was detected using streptavidin-
peroxidase (Sigma Chemical Co., St Louis, USA) for
30 min at room temperature, followed by the addition of
2,2′-azinobis (3-ethylbenzthiazolinesulfonic acid) (ABTS;
Sigma Chemical Co., St Louis, USA) and 30% hydrogen
peroxide (Merck, Darmstadt, Germany) as the substrate.
The reaction was stopped with 20% sodium dodecyl
sulphate (Merck, Darmstadt, Germany), and the absorb-
ance was read at 405 nm in a spectrophotometer (Spec-
tra Max 250; Molecular Devices, Sunnyvale, CA). A
standard curve was constructed for each cytokine
by using different dilutions of human recombinant
cytokines.Table 1 Ex-vivo analysis of CD4+, CD8+ T cells and B cells
(CD20+) from malaria patients and control individuals
Cells Malaria Controls
CD4+ 45,6 ± 15,7 45,3 ± 12,4
CD8+ 23,4 ± 7,9 24 ± 10,3
CD20+ 20,1 ± 22,9 10,7 ± 9,6
(Mean ± standard deviation).Statistical analysis
For unpaired analyses, the nonparametric Mann–Whit-
ney test was used to determine the significance of differ-
ences in plasmatic concentrations of cytokines between
patients with acute malaria infection and control indi-
viduals and also among patient antibody responses. The
Spearman rank correlation coefficient test was used to
evaluate the correlation of epidemiological and immuno-
logical data. Student’s t-test was used to analyse differ-
ences in mean values, and chi-square analysis was
applied to compare the prevalence of positive responses.
Spearman rank coefficient test was also used to analysethe variable correlations. p values less than 0.05 were
considered significant.
Results
Characteristics of study groups
Blood collection was performed at the day of diagnosis,
before malaria treatment. Patients sought health care at
Brazilian health services 6.8 ± 6.9 days after onset of
symptoms. Throughout the study period, a total of 35
samples were collected from uncomplicated malaria
cases (malaria group) with P. falciparum (n = 12) or
P. vivax (n = 23) infection and from individuals (n = 17)
living also in downtown Paragominas but with no history
of current or previous malaria episodes (control group).
The malaria group consisted of 6 female and 29 men
with age ranging from 12 to 67 years old (31 ± 14 years
old). Twenty six percent denied prior malaria infection
and 64% reported 4.7 ± 6.0 previous malaria episodes
during life. The individuals from the malaria group
claimed living in malaria endemic area for 19 ± 13 years.
All of them presented, at time of blood sampling, symp-
toms and positive thick blood smears, with a parasit-
aemia ranging from 50 to 3,000 (1,213 ± 1,088) parasites/
μl for P. falciparum and 75 to 5,000 (1,640 ± 1,220) para-
sites/μl for P. vivax.
Individuals from the control group claimed living in
malaria endemic area for 18 ± 13 years and corresponded
to 10 women and seven men with average age of 35 ±
7 years. All individuals were negative for malaria para-
sites as assessed by thick blood films.
Viability of peripheral blood mononuclear cells (PBMC)
after thawing
The viability of mononuclear cells after thawing was
analysed and the percentages observed in malaria pa-
tients (78.1 ± 12.5%) were similar to those found in
healthy individual (78.7 ± 19.6%). Likewise, no difference
was observed when comparing the viability of PBMC
from P. falciparum and P. vivax malaria patients.
Phenotypic analysis of ex-vivo PBMC samples
The phenotypic analysis of ex-vivo PBMC revealed that,
as expected, CD4+ T cells were found more frequently
than CD8+ and CD20+ cells, in both malaria and control
individuals (Table 1). No difference was observed when
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cells between malaria and control individuals.
Cellular activation ex-vivo and after 96 hours culture
The cellular activation was analysed by the expression of
interleukin-2 receptor (IL-2R), using an anti-CD25
monoclonal antibody.
In ex-vivo analysis, PBMC from malaria individuals
presented higher levels of cellular activation (27.2 ±
14.2%) than control individuals (18.2 ± 11.9%). No differ-
ence in cellular activation was observed when comparing
P. falciparum (24.7 ± 16.8) and P. vivax (31.4 ± 18.3)
infected individuals (Figure 1). In malaria individuals,
CD4+ T cells were more activated (16.1 ± 12.2%) than
CD8+ T cells (3.2 ± 3.3%). The same result was observed
when comparing P. vivax (CD4+: 17.6 ± 13.9; CD8+:
3.6 ± 3.7) and P. falciparum (CD4+: 13.6 ± 8.2; CD8+:A
B
Figure 1 Ex-vivo analysis of the expression of IL-2R in PBMC by
cytometry flow. (A) PBMC from malaria patients (n = 34) and
control individuals (n = 16) and (B) PBMC from individuals infected
with P. falciparum, P. vivax and control individuals. *p = 0.01, malaria
versus control individuals; ** p = 0.009 P vivax versus control
individuals. Lines represent geometric mean.2.3 ± 2) infected individuals. However, no difference was
observed in the levels of cellular activation of CD4+ or
CD8+ between P. falciparum and P. vivax infected indi-
viduals (Figure 2).
In 96 h culture in the presence of PvMSP-119 (malaria,
50.9 ± 23.6%; controls 15.7 ± 26.8) or PSS1 crude antigen
(malaria, 47.2 ± 23.4%; controls 11.6 ± 23.9%), higher
levels of cellular activation were observed in malaria
group than in controls individuals. The same result was
observed when comparing P. vivax (PvMSP119 48.9 ±
24.3; PSS1 42.7 ± 23.5) and P. falciparum (PvMSP119
54.6 ± 23.5; PSS1 55 ± 22.6) infected individuals. However,B
C
Figure 2 Ex-vivo analysis of the expression of IL-2R by
cytometry flow in T cells subpopulations. CD4+/IL2R + and CD8
+/IL2R + T cells from (A) malaria patients (n = 34), (B) individuals
infected with P. falciparum and (C) individuals infected with P. vivax.
CD4+ versus CD8+: *p < 0.0001, ** p = 0.0006, *** p < 0.0001. Lines
represent geometric mean.
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tion between P. falciparum and P. vivax infected individ-
uals (Figure 3). These activated cells were mainly CD4+
T cells (Figure 4).
Proliferative response
After 96 h of culture, no difference was observed when
comparing different stimuli in malaria individuals. Also,
in control individuals, no proliferative response was ob-
served when cells were cultivated without stimulus or in
presence of both PvMSP-119 and PSS1 crude antigen.
However, in presence of PHA, the proliferative response
was two fold higher in control individuals than that ob-
served in malaria patients (Figure 5).
Cytokine profile
Plasmatic cytokine levels
Higher plasmatic levels of IFN-γ and IL-10 as well as
lower TNF levels were observed in both malaria andFigure 3 Analysis of cellular activation by the expression of
IL-2R after 96 h culture in presence of PvMSP-119 and PSS1
crude antigen by cytometry flow. (A) PBMC from malaria patients
(n = 35) and control individuals (n = 17) and (B) PBMC from individuals
infected with P. falciparum, P. vivax and control individuals. *p = 0.001
for PvMSP119 and p = 0.0003 for PSS1, malaria versus control individuals;
** p = 0.009 for P. falciparum versus controls and p = 0.003 for P. vivax
versus controls; *** p = 0.004 for P. falciparum versus controls and
p = 0.001 for P. vivax versus controls.
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Figure 4 Cytometry flow analysis of T cells activation (IL-2R+)
after 96 h of culture in the presence of PvMSP-119 and PSS1
crude antigen. CD4+/IL2R + and CD8+/IL2R + T cells from (A)
malaria patients (n = 35); individuals infected with P. falciparum and
P. vivax in presence of (B) PvMSP119 and (C) PSS1. *p = 0.0002 for
PvMSP119 and p = 0.003 for PSS1, CD4
+ versus CD8+; **p = 0.02 for
P. falciparum and p = 0.003 for P.vivax CD4+ versus CD8+; ***p = 0.02
for P. vivax.
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Figure 5 Analysis of cellular proliferation after 96 hour culture
by cytometry flow using a CFSE vital staining. PBMC from
malaria patients and control individuals in the absence or presence
of plasmodial antigens (PvMSP-119 and PSS1 crude antigen) or PHA
mitogen. *p = 0.02 malaria versus control individuals
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uals (Figure 6). No difference was observed between
TNF and IL-10 levels when comparing P. falciparum- or
P. vivax-infected individuals. However, higher levels of
IFN-γ were noted in P. vivax- infected individuals
(p = 0.03) (Figure 7).
In malaria patients, no correlation was observed be-
tween levels of plasmatic TNF or IFN and age, the num-
ber of previous malaria infection, time of residence in
malaria endemic area, parasitaemia or the time elapsed
between first symptoms and malaria diagnosis. However,
a negative correlation was detected between plasmatic
levels of IL-10 and the number of previous malaria in-
fection (p = 0.0186; r = − 0.3958) in malaria individuals.
Cytokine levels from culture supernatant of PBMC
In the 96 h supernatant culture as represented in Figure 8,
the dynamics of cytokine responses differed from those
depicted in the study of the plasma samples. In presenceFigure 6 Plasmatic concentrations of cytokines evaluated by ELISA as
individuals, malaria patients, individuals infected with P. falciparum and ind
individuals and control versus P. vivax; ** p = 0.001 for controls versus malar
malaria and controls versus P. vivax; p = 0.001 controls versus P. falciparum.of PvMSP-119 stimulus, higher levels of TNF were
observed in supernatant 96 h culture of malaria indi-
viduals’ cells when comparing with both PSS1 crude
antigen (P = 0,03) or without stimulus (P = 0,0006). No
statistical difference was observed between cytokines
levels from supernatant cultures of P. falciparum- or
P. vivax-infected patients. In malaria patients, a posi-
tive correlation was observed between the levels of
TNF obtained from supernatants of cultures stimulated
with PvMSP-119 and the time of living in an endemic area
(P = 0.001, r = 0.5196).
Regarding to IL-10, positive correlation was observed
between the levels of this cytokine obtained from superna-
tants of PBMC stimulated with PvMSP1-19 (P = 0.0288,
r = 0.3752) or with PSS1 (P = 0.033, r = 0.3661) and the
time of residence in endemic area. Positive correlation was
also observed between the number of previous malaria in-
fection and the levels of IFN-γ when PBMC were stimu-
lated with PvMSP-119 (P = 0.0004, r = 0.5704).says. Levels of TNF, IFN-γ and IL-10 in plasma samples from control
ividuals infected with P. vivax. *p = 0.01 control versus malaria
ia; p = 0.0007 control versus P. vivax; *** p < 0.0001 controls versus
*Figure 7 Plasmatic concentrations of IFN-γ. Levels of IFN-γ in
plasma samples from P. falciparum and P. vivax malaria patients. *p
= 0.03, P. falciparum versus P. vivax.
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High frequency (30/35, 86%) of malaria patients present-
ing antibodies to IgG, IgM, IgE type and IgG isotypes
against PvMSP-119 was noticed. The frequencies of mal-
aria patients presenting antibodies against PvMSP-119-α
-α
-γ
-γ
*
A
B
Figure 8 Analysis of cytokines concentrations in plasma and in
supernatant of the cultures measured by ELISA. Levels of TNF,
IFN-γ and IL-10 in plasma samples and in supernatant of the PBMC
cultures from (A) control individuals (n = 17) and (B) malaria patients
(n = 35). *p = 0.03, PvMSP-119 versus PSS1; p = 0.0006, PvMSP-119
versus without stimulus.were 63% (22/35), 80% (28/35) and 51% (18/35) for IgG,
IgM and IgE class, respectively (Figure 9). The percent-
age of patients presenting anti-PvMSP-119 IgM anti-
bodies was higher than the frequency of patients
presenting IgE antibodies (p = 0.02). Besides the IgM fre-
quency, these patients presented also higher levels of
anti PvMSP-119 IgM antibodies (p = 0.004) (Figure 10).
No correlation between IgG or IgM antibodies and age,
time of residence in malaria-endemic area, parasitaemia,
number of previous malaria infection and time since last
malaria infection was observed. However, the levels of
IgE antibodies was inversely correlated with the number
of previous malaria episodes (p = 0.01, r = −0.4061). The
frequency and the levels of IgG, IgM and IgE antibodies
against PvMSP-119 were higher in patients infected with
P. vivax than in patients infected with P. falciparum
(Figures 11 and 12).
None of the 17 control individuals had detectable
IgG, IgM or IgE antibodies against PvMSP119 or PSS1
crude antigen. The prevalences of IgG1, IgG2, IgG3 and
IgG4 subclasses in IgG-positive malaria patients were,
respectively, 64% (14/22), 86% (19/22), 14% (3/22) e
91% (20/22). PvMSP-119-induced antibodies were pre-
dominantly of non-cytophilic subclasses (Figure 13).
Anti-PvMSP-119 IgG3 antibodies were less prevalent
than IgG1, IgG2 and IgG4 antibodies (p = 0.001 IgG3
versus IgG1; p < 0.0001 IgG3 versus IgG2; p < 0.0001
IgG3 versus IgG4). The levels of anti-PvMSP-119 IgG4
antibodies were higher than the levels of IgG1, IgG2
and IgG3 antibodies (p = 0.04 IgG4 versus IgG1; p = 0.03
IgG4 versus IgG2; p = 0.01 IgG4 versus IgG3) (Figure 14).
No correlation between IgG1, IgG2, IgG3 or IgG4 and
age, time of residence in malaria-endemic area, parasit-
aemia, number of previous malaria infection and time
elapsed after last malaria attack was observed. Also, no
association was observed in the prevalence or levels of
IgG1, IgG2, IgG3 and IgG4 antibodies against PvMSP-119
when comparing P. falciparum- and P. vivax-malaria
patients.
Positive correlations were observed between anti-
PvMSP-119 IgG antibodies and IL-10 levels in P. vivax-
malaria patients (p = 0,0171; r = 0,7621); anti-PvMSP-119
IgM antibodies and IFN-γ levels in P. falciparum-mal-
aria patients (p = 0,0036; r = 0,7666) and; anti-PvMSP-119
IgE antibodies and TNF in both P. vivax- and P. falcip-
arum-malaria patients (P. vivax: p = 0,0432; r = 0,4081;
P. falciparum: p = 0,0455; r = 0,5856).
Discussion
In the present work, the profile of acquired cellular and
antibody immune responses against PvMSP-119 was
evaluated in individuals naturally exposed to P. vivax
and P. falciparum infections in a malaria-endemic area
in the north-western Amazon region of Brazil.
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Figure 9 Analysis of antibodies in sera from malaria patients. Frequency of malaria patients (n = 35) with IgG, IgM and IgE antibodies against
PvMSP-119. *p = 0.02, IgM versus IgE.
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http://www.malariajournal.com/content/12/1/326It is well known that suboptimal cryopreservation
could result in a significant decrease of cell number and
viability, causing alterations on the cellular phenotype
and on the immune response to specific antigens. To
avoid troublesome events, a protocol to successfully re-
covery PBMC after freezing and thawing was previously
standardized [34]. Thus, in the present study, an import-
ant frequency of mononuclear cell viability after thawing
was observed (around 78%), regardless the individuals
being infected or not. Because 75% PBMC viability is re-
quired for lymphocyte proliferation assays, representing
the ability of cells to respond to the antigenic or mito-
genic stimulation, independently of the nature orFigure 10 Analysis of IgG, IgM and IgE antibodies levels against PvM
mean with standard deviation. Continuous line represents cut off.intensity of the stimulus [35], the cryopreservation pro-
cedure seems not have been a limiting factor in the
present study.
The phenotypic analysis of ex-vivo PBMC revealed
that CD4+ T cells were found more frequently than
CD8+ and CD20+ cells, in both malaria and control indi-
viduals. In malaria individuals, a higher prevalence of ac-
tivated CD4+ than CD8+ T cells was observed, in both
ex-vivo and in 96 h culture in presence of PvMSP-119
and PSS1 antigen. It can be speculated that CD4+ T cells
were the most stimulated cells due the nature of anti-
genic stimulus because CD4+ T cells are activated by the
parasite in blood stage, while CD8+ T cells are most*
SP-119 in malaria patients.*p = 0.005, IgM versus IgG. Lines represent
**
*
Frequency (%)
Figure 11 Prevalence of antibody responses against PvMSP-119 in malaria infected individuals. Frequency of IgG, IgM and IgE antibodies
in individuals with P. vivax or P. falciparum malaria. * p = 0.02 for IgE, p = 0.03 for IgM and IgG, P. vivax versus P. falciparum.
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http://www.malariajournal.com/content/12/1/326often activated during the hepatic stage of parasite life
cycle [36].
Low proliferative responses in the presence of MSP-119
of P. falciparum and Plasmodium chabaudi chabaudi
have already been demonstrated [37,38]. The results also
showed a low proliferative response against PSS1 crude
antigen or PvMSP-119 after 96 h culture. This low pro-
liferative response may occur because the majority of*
*
Figure 12 Levels of IgG, IgM and IgE antibodies. Analysis of antibodies
individuals. * p = 0.01 for IgG, p = 0.04 for IgM, p = 0.003 for IgE, P. vivax versactivated cells undergo activated-induced cell death, an
active cell suicide mechanism of widespread biological
importance that constitutes the physiological response
of normal cells to activation and is believed to control
the number of antigen-stimulated cells during the im-
mune response [39].
Anti-inflammatory cytokines are involved in a feed-
back mechanism to regulate the expression of pro-*
levels against PvMSP-119 in P. vivax- or P. falciparum- infected
us P. falciparum. Lines represent mean with standard deviation.
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Figure 13 Frequency of IgG subclasses. Prevalence of IgG1, IgG2, IgG3 and IgG4 antibodies against PvMSP-119 in IgG-positive malaria patients
(n = 35). * p = 0.001, IgG3 versus IgG1; p < 0.0001, IgG3 versus IgG2 and IgG4.
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http://www.malariajournal.com/content/12/1/326inflammatory cytokines, and prevent the pathological ef-
fects that may result from their continuous secretion.
Previous in vitro studies have shown that IL-10 sup-
presses the expression of malaria parasite-induced pro-
duction of TNF by PBMC [40]. In fact, in the present
study, high plasmatic levels of IL-10 and low plasmatic
levels of TNF were observed in malaria patients.
Parasite clearance seems to be related to IL-10 and
IFN-γ levels. Here, an intense secretion of IFN-γ and IL-
10 as detected by dosage of plasmatic levels, were shown
in malaria patients. However no correlation was found
between parasitaemia and IFN-γ or IL-10 levels. TheIgG1 IgG2
0
5
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15
20
25
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at
io
Figure 14 Levels of IgG1, IgG2, IgG3 and IgG4 antibodies against PvM
IgG4 versus IgG2; p = 0.01, IgG4 versus IgG3. Lines represent mean with stanhigh levels of IL-10 and IFN-γ are in agreement with
previous clinical reports that IL-10 is up-regulated in
concern with IFN-γ [41,42], suggesting that IL-10 may
be up-regulated as a direct consequence of IFN-γ pro-
duction as part of homeostatic feedback mechanism to
limit IFN-γ-mediated pathology, as is seen in murine
malaria infections [43].
IL-10 levels were similar in P. vivax and P. falciparum
infected individuals. However, besides plasmodial spe-
cies, other factors, like the number of previous malaria
infections, may influence the levels of this and other cy-
tokines. In fact, a negative correlation between numberIgG3 IgG4
*
SP-119 in malaria patients. * p = 0.04, IgG4 versus IgG1; p = 0.03,
dard deviation. Dotted line represents cut off.
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http://www.malariajournal.com/content/12/1/326of previous malaria infections and IL-10 levels was
found. In addition, previous studies have shown that an
adaptive type 1 regulatory CD4+ cells have been identi-
fied as the main source of IL-10 in experimental murine
infection with Plasmodium yoelii [44], while in P.
chabaudi infections in mice, an activated effector TH1
cells were major IL-10 producers [45]. Understanding
how these regulatory cells are induced could help to ex-
plain differences in IL-10 production in human malaria.
High production of TNF in malaria individuals is re-
lated to the development of severe malaria. In the
present work, lower than expected plasmatic TNF levels
(lower than those observed in control individuals) were
detected in malaria patients. Interestingly, PvMSP-119-
stimulated PBMCs from malaria patients showed higher
TNF response than those recorded in both PSS1-
stimulated and non-stimulated PBMCs. The production
of TNF in recall to PvMSP-119 may suggest a protective
role of PvMSP-119 immune response because TNF has
been related to parasite clearance.
A great majority of studied individuals presented anti-
bodies against PvMSP-119, independently of the reported
number of previous malaria attacks or the time of resi-
dence in a malaria-endemic area, indicating that this pro-
tein is immunogenic in natural conditions of exposure
and seems to be independent of the time of exposure. The
high immunogenicity of PvMSP-119 may be reflex of its
limited polymorphism, because independent groups dem-
onstrated that PvMSP-119 is conserved [17,46,47]. An-
other possible explanation is that PvMSP-119 is the single
fragment that remains on the parasite surface during red
cell invasion through glycosylphosphatidylinositol (GPI)
anchor [13] and studies have described GPI as a potent ag-
onists of toll-like receptors that may provide the adjuvant
required for stronger immune responses [48].
Anti-PvMSP-119 antibodies were not detected in the
sera of five individuals from malaria group (one with
vivax and four with falciparum malaria). The absence of
anti-PvMSP-119 antibodies could be related to immuno-
suppression observed in humans in malaria infection
[49,50], however, this hypothesis seems unlikely because
these non-responders individuals presented antibodies
against PSS1 crude antigen. Another possible explan-
ation for the absence of these antibodies is that PvMSP-
119-specific B cells were present, although circulating
antibodies titers were undetectable. Alternatively, the
lack of PvMSP-119 antibody response may be due the
genetic restriction of immune response that has been de-
scribed to several plasmodial recombinant proteins and
synthetic peptides [24,51-55]. However, in a recent study
performed in the Brazilian Amazon region, no associ-
ation between HLADRB1* and HLADQB1* allelic
groups and the antibody response against PvMSP-119
was found [24].Considering that different Plasmodium antigens in the
same population as well as the same Plasmodium anti-
gen in different populations can induce different anti-
body profiles, it was also evaluated the frequency and
levels of IgG, IgM and IgE class and IgG subclass against
PvMSP-119. IgM antibodies were the most prevalent and
the one with the highest levels. PvMSP-119-induced IgG
antibodies were predominantly of non-cytophilic sub-
classes. Different data have been reported for individuals
living in other Brazilian-endemic areas with different
levels of exposure where the PvMSP-119-induced anti-
bodies were predominantly of IgG1 subclass [20,23]. Dif-
ferences in antibody profile may be due to transmission
intensity. In fact, previous study has demonstrated that
the levels of IgG1 and IgG3 specific antibodies were low
among individuals with long-term exposure (~19 years)
when compared to subjects less and sporadically ex-
posed (< 1 year) [20]. In this concern, one must
emphasize that the individuals from malaria group
claimed living in malaria endemic area for 19 years. An-
other additional hypothesis could be related to cytokine
modulation of specific antibodies production because
IL-10 has been reported to demonstrate both potentiat-
ing and inhibiting IgE and increasing IgG4 productions
[56] as well as to be associated with IgM antibodies
against P. vivax [57]. In addition, associations between
polymorphism in cytokine genes and anti-plasmodial
antibody response have been reported [53]. One other
possibility could be the context of the response because
co-infection with helminths is known to shift the Th1 to
the Th2 pattern of immune response modulating the IgG
subclass expression. Independently of its origin, the dif-
ferences between antibody profile reported in the
present study and the aforementioned underline the
importance of conducting immunoepidemiological
studies in different malaria endemic areas where
transmission intensities and human genetic back-
ground are different.
Associations between antibody responses with time
of residence and/or number of previous episodes have
been commonly reported to several malaria antigens
[52,58,59]. However, in the present study, no association
between levels of PvMSP-119 antibodies and number of
previous malaria episodes was observed. This finding
may reflect that people living for a longer period of time
in the region may have acquired some degree of clinical
immunity after experiencing a number of infections,
therefore, reporting less episodes of clinical malaria in
the more recent years. Interestingly, only the levels of
IgE antibodies were inversely correlated with the num-
ber of previous malaria episodes. Thus, it can be sup-
posed that higher levels of IgE antibodies may have an
important role against clinical malaria. Similar results
were already reported that shown that high levels of
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http://www.malariajournal.com/content/12/1/326malaria specific IgE were associated with reduced risk
for subsequent clinical malaria episodes [60].
In this study the frequency and the levels of IgG, IgM
and IgE antibodies against PvMSP-119 were higher in in-
dividuals infected with P. vivax than P. falciparum or
who had reported the last malaria episode due P. vivax.
Similar results were reported elsewhere where sera from
subjects who had had P. vivax in their last malaria clin-
ical episode presented higher levels of antibodies when
compared with those whose last malaria episode was
due to P. falciparum [20].
The individuals infected with P. falciparum studied in
this work reported previous infection with P. vivax. This
may explain the recognition of PvMSP119 antigen by
antibodies from individuals infected with P. falciparum.
However, the similarity between PfMSP1 and PvMSP1
antigens may also explain, at least in part, the recogni-
tion of PvMSP1 by patients infected with P. falciparum,
although a recent study has shown that sera from immu-
nized mice with PfMSP119 or PvMSP119 failed to cross-
react with heterologous antigen [61].
In conclusion, the results presented here shows that
PvMSP-119 was able to induce a high cellular activation
leading to production of TNF, emphasizing the high im-
munogenicity of PvMSP-119 in naturally exposed indi-
viduals and therefore its potential as a malaria vaccine
candidate.
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